Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Nat Rev Drug Discov. 2022 Feb 1;21(4):261–282. doi: 10.1038/s41573-021-00387-y

Table 1.

Shared neoantigens. Most frequent tumour type and mutation frequency in the respective tumour entity has been estimated using SNV data from TCGA. Index tumours are those, which are most frequently affected. MUT: mutation, RE: restriction element. MHC allele frequencies were derived from the NCBI dbMHC database213.

Gene(s) Mutation (MUT) Reference Restriction element (RE)
c% of RE in European/North American population, Population with next highest % of RE and its % of RE)
SNVs
KRAS G12V 42 HLA-A*11:01 (4.2%, Oceania: 20.7%)
KRAS G12D 42,108,146 HLA-A*02:01 (22.3%, South America: 22.1%), HLA-C*08:02 (-), HLA-DRB1*08:01 (1.2%, North Africa: 1.4%)
IDH1 R132H 52 HLA-DRB1*01:01 (4.3%, North-East Asia: 5.7%)
TP53 R175H 17,43 HLA-A*02:01 (22.3%, South America: 22.1%), HLA-DRB1*13:01 (2.37%, South India: 13.8%)
H3.3 K27M 214,215 HLA-A*02:01 (22.3%, South America: 22.1%), HLA-DR1 (-)
JAK2 V617F 216 HLA-A2 (-)
PIK3A H1047L 217 HLA-A*03:01 (8.6%, South India: 8.0%)
BRAF V600E 218 HLA-DQB1*03
CDK4 R24C 1 HLA-A2.1 (22.3%, South America: 22.1%)
CDK12 E928K 11 HLA-A*11:01 (4.2%, Oceania: 20.72%)
NRAS Q61R 219 HLA-A*01:01 (10.0%, North Africa: 12.59%)
CTNNB1 F37S 220 HLA-A24+ (-)
INDELs
GAS7 H225Y 11 HLA-A*02:01 (22.3%. South America: 22.1%)
NPM 4 bp hotspot insertion in exon 12 221 HLA-A*02:01 (22.3%. South America: 22.1%)
CALR INDELs in exon 9 98 Mixed
TGFβRII 1bp deletion in poly(A)10 tract (nucleotides 709-718) 222,223 HLA-A2+ (-), HLA-DPB1*03:01 (8.1%, Central America: 10.0%), HLA-DRB1*14:01 (23%, SouthEast Asia 13.4%)
Fusion Genes
BCR-ABL fusion protein b3a2 224–227 HLA-A3+ (-),HLA-DR+ (-)
dek-can t(6;9) 226 HLA-DR53+ (-)
SYT-SSX t(X; 18)(p11;q11) 228,229 HLA-A24+ (-)
pml/RAR alpha - 230 HLA-DR11+ (-)
PAX-FKHR t(2;13) 231 HLA-B7+ (-)
ETV6-AML1 t(12;21) 232,233 Mixed (-)